Immunocore announcement coming soon –


Immunocore announces upcoming presentations at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Overall survival (OS) update Data of Phbase 1b metastatic cutaneous melanoma trial

Oactual presentation as part of the clinical sciences symposium and two poster presentations

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Maryland, USA, May 26, 2022) Immunocore Holdings plc (IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering the development of a new class of bispecific T-cell receptor (TCR) immunotherapies designed to treat a wide range of diseases, including cancer, autoimmune diseases and infectious diseases, today announced that it will oral presentation and two poster presentations at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, to be held June 3-7, 2022.


Title: Updated Overall Survival (OS) Data from the Phase 1b Study of Tebentafusp (tebe) Monotherapy or in Combination with Durvalumab (durva) and/or Tremelimumab (treme) in Metastatic Cutaneous Melanoma (mCM) )

  • Presenter: Mark Middleton
  • Date and time: June 5, 2022; 9:45 a.m. CDT
  • Session: Colloquium of clinical sciences: Bispecifics: are two better than one?
  • Summary IDENTIFIER: 104


Title: Treatment with tebentafusp beyond radiographically active disease (PD) in metastatic uveal melanoma (mUM)

  • Presenter: ryan sullivan
  • Date and time: June 6, 2022; 1:15 p.m. – 4:15 p.m. CDT
  • Session: Melanoma / Skin cancers
  • Summary ID: 9585

Title: Analysis of the effect of systemic corticosteroids on tebentafusp survival in a phase 3 trial in metastatic uveal melanoma

  • Presenter: Alexandra Ikeguchi
  • Date and time: June 6, 2022; 1:15 p.m. – 4:15 p.m. CDT
  • Session: Melanoma / Skin cancers
  • Summary ID: 9584

Title: Overall survival (OS) in metastatic uveal melanoma: a summary of recent prospective trials

  • Author: Josep M. Piulats
  • Post only

Presentations and posters will be available to registered participants on the ASCO website from June 3-7, 2022.


About uveal melanoma
Uveal melanoma is a rare and aggressive form of melanoma, which affects the eye. Although it is the most common primary intraocular malignancy in adults, the diagnosis is rare and up to 50% of people with uveal melanoma will eventually develop metastatic disease. Unresectable or metastatic uveal melanoma generally has a poor prognosis and had no approved treatment until KIMMTRAK.

KIMMTRAK is a novel bispecific protein composed of a soluble T cell receptor fused to an anti-CD3 immuno-effector function. KIMMTRAK specifically targets gp100, a lineage antigen expressed in melanocytes and melanoma. It is the first molecule developed using Immunocore’s ImmTAC technology platform designed to redirect and activate T cells to recognize and kill tumor cells. KIMMTRAK has received Breakthrough Therapy Designation, Fast Track Designation and Orphan Drug Designation by the US FDA, Fast Track Review by the EMA and Promising Innovative Medicine (PIM) Designation under the UK Early Access to Medicines Scheme for metastatic uveal melanoma.

About the Phase 3 IMCgp100-202 trial
IMCgp100-202 (NCT03070392) is a pivotal randomized trial that evaluated the overall survival (OS) of KIMMTRAK (tebentafusp-tebn) versus investigator’s choice (either pembrolizumab, ipilimumab, or dacarbazine) in HLA- A*02:01 positive previously untreated mUM patients. KIMMTRAK demonstrated unprecedented benefit on OS with a hazard ratio (RR) in the intent-to-treat population in favor of KIMMTRAK, RR=0.51 (95% CI: 0.37, 0.71); p

About ImTAC® Molecules
Immunocore’s proprietary T-cell receptor (TCR) technology generates a new class of bispecific biologics called ImmTAC molecules (monoclonal immune mobilizing TCRs against cancer), designed to redirect the immune system to recognize and kill cells cancerous. ImmTAC molecules are soluble TCRs designed to recognize intracellular cancer antigens with ultra-high affinity and selectively kill these cancer cells via an anti-CD3 immune activation effector function. Based on the demonstrated mechanism of T-cell infiltration in human tumors, ImmTAC’s mechanism of action has the potential to treat hematologic and solid tumors regardless of mutational burden or immune infiltration, including “cold” immune tumors with low mutation rates.

About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a new class of bispecific TCR immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a wide range of diseases, including cancer, autoimmune diseases, -immune and infectious diseases. Leveraging its proprietary, flexible and ready-to-use ImmTAX platform, Immunocore is developing an in-depth pipeline across multiple therapeutic areas, including five clinical-stage programs in oncology and infectious diseases, advanced preclinical programs in auto- immune and several earlier preclinical programs. Immunocore’s most advanced oncology TCR therapy, KIMMTRAK (tebentafusp-tebn), has been approved by the US FDA for the treatment of HLA-A*02:01 positive adult patients with unresectable or metastatic uveal melanoma who have demonstrated overall survival benefit in a phase 3 randomized clinical trial in metastatic uveal melanoma, a cancer that has historically been shown to be unresponsive to other immunotherapies.

Forward-looking statements
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included in this press release are forward-looking statements. . These statements include, but are not limited to, statements regarding the European Commission’s final decision on Immunocore’s marketing authorization application and approval of KIMMTRAK in the European Union; marketing and therapeutic potential of KIMMTRAK for metastatic uveal melanoma (mUM); the expected clinical benefits of KIMMTRAK, including improvement in overall survival; expectations regarding the ability to reach patients in a timely manner, including obtaining future regulatory approval in the respective European countries, the United Kingdom, Australia and Canada; KIMMTRAK’s value proposition in mUM and benefits as an orphan indication, including expectations regarding potential market size opportunity; Immunocore’s sales and marketing plans in the United States and the European Union; and tebentafusp’s future development plans, including the timing or likelihood of expansion into additional markets or geographies. All forward-looking statements are based on management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those stated or implied. by these forward-looking statements, many of which are beyond the Company’s control. These risks and uncertainties include, but are not limited to, the impact of the ongoing COVID-19 pandemic and the Omicron variant on the Company’s business, strategic clinical trials and financial condition; Immunocore’s ability to maintain regulatory approval of KIMMTRAK; its ability to execute its go-to-market strategy for KIMMTRAK; its ability to develop, manufacture and commercialize its other product candidates, including plans for the future development of tebentafusp and other product candidates, including the timing or likelihood of expansion into other markets or geographies; the commercial supply of KIMMTRAK or any future approved product, and the introduction, marketing and sale of KIMMTRAK or any future approved product; Immunocore’s ability and plans to continue to establish and expand a commercial infrastructure and to successfully launch, market and sell KIMMTRAK; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or future regulatory approval; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it develops; unexpected safety or efficacy data observed during preclinical studies or clinical trials; lower than expected clinical trial site activation or recruitment rates; changes in anticipated or existing competition; Immunocore’s ability to obtain, maintain and enforce intellectual property protection for KIMMTRAK or any product candidates it develops; and the success of Immunocore’s current and future collaborations, partnerships or licensing agreements. These and other risks and uncertainties are described in more detail in the section titled “Risk Factors” in Immunocore’s filings with the Securities and Exchange Commission, including Immunocore’s most recent annual report on form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on March 25, 2021, together with discussions of potential risks, uncertainties and other important factors in subsequent filings of the Company with the Securities and Exchange Commission. All information contained in this press release is as of the date of publication, and the Company assumes no obligation to update such information except as required by law.


Debra Nielsen, Communications Manager
Such. : +1 (610) 368-8602
E : [email protected]
Follow on Twitter: @Immunocore

Advice Strategic communications (institutional and financial)
Mary-Jane Elliott/Chris Welsh/Jessica Hodgson
Such. : +44 (0)203 709 5700
E : [email protected]

Investor Relations
Clayton Robertson, Head of Investor Relations
Such. : +1 215-384-4781
E : [email protected]


About Catriona

Check Also

Nemaura receives a provisional purchase order from Middle

LOUGHBOROUGH, ENGLAND, Oct. 12, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or …